MENU
+Compare
SPRY
Stock ticker: NASDAQ
AS OF
Feb 3 closing price
Price
$10.15
Change
-$1.43 (-12.35%)
Capitalization
1B

SPRY ARS Pharmaceuticals Forecast, Technical & Fundamental Analysis

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis... Show more

SPRY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for SPRY with price predictions
Feb 03, 2026

Aroon Indicator for SPRY shows an upward move is likely

SPRY's Aroon Indicator triggered a bullish signal on January 22, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 192 similar instances where the Aroon Indicator showed a similar pattern. In of the 192 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 54 cases where SPRY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRY advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for SPRY moved out of overbought territory on January 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on January 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRY as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for SPRY turned negative on January 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

SPRY moved below its 50-day moving average on January 28, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for SPRY crossed bearishly below the 50-day moving average on February 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SPRY broke above its upper Bollinger Band on January 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SPRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.789) is normal, around the industry mean (27.519). P/E Ratio (151.250) is within average values for comparable stocks, (51.491). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.893). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (7.358) is also within normal values, averaging (331.843).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
SPRY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

SPRY is expected to report earnings to fall 18.35% to -42 cents per share on March 19

ARS Pharmaceuticals SPRY Stock Earnings Reports
Q4'25
Est.
$-0.42
Q3'25
Missed
by $0.06
Q2'25
Est.
$-0.46
Q1'25
Missed
by $0.01
Q4'24
Beat
by $0.61
The last earnings report on November 10 showed earnings per share of -51 cents, missing the estimate of -46 cents. With 1.04M shares outstanding, the current market capitalization sits at 1.00B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
11682 El Camino Real
Phone
+1 858 771-9307
Employees
26
Web
https://www.ars-pharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AMTAX10.880.16
+1.49%
AB All Market Real Return A
AXVIX19.940.13
+0.66%
Acclivity Small Cap Value I
HSMVX13.820.01
+0.07%
Hartford Small Cap Value R6
PIOTX25.36-0.02
-0.08%
Victory Pioneer Core Equity A
PJFOX65.69-1.39
-2.07%
PGIM Jennison Growth R2

SPRY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRY has been loosely correlated with LPCN. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRY jumps, then LPCN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRY
1D Price
Change %
SPRY100%
+3.10%
LPCN - SPRY
63%
Loosely correlated
+0.11%
REPL - SPRY
31%
Poorly correlated
-0.78%
ACAD - SPRY
30%
Poorly correlated
+3.98%
CLDX - SPRY
29%
Poorly correlated
+0.24%
EYPT - SPRY
29%
Poorly correlated
-1.70%
More